Questions I would like answered: The India/Taiwan deal, there...

Questions I would like answered:

The India/Taiwan deal, there was mention of an Israeli Government Insurer whereby GMV was able to receive upfront payments immediately upon receipt of an order. Is this arrangement in place for all the current binding agreements, and if so, does this mean we can expect to receive payments immediately from the China and Greece agreements once CFDA is achieved (as this appears to be the condition precedent for those deals).

The Chinese subsidiary was meant to make best endeavors to secure $10m in grants or loans. Is this still being pursued? Are we likely to get and help in the near term from them to assist with the ramp up?

The GMV Patch was aiming to obtain FDA by 2017. What is the current status of this application? Are there trials involved? What has been the feedback and when might we anticipate receiving FDA.

Where will the GMV Patch be manufactured, and what is the production capacity?

Can we expect to secure some deals in Europe in the near future, as this is the only place we have received approval for both the Prizma and Patch, so there is nothing preventing us from currently entering this market, other than production.

The current agreements for the Prizma exceed 1 million units per year, yet the factory is currently only able to produce 1 million units per year. Is the factory likely to expand once the orders exceed capacity?

The Patch is attached by an adhesive. Does this require male patients to shave their chest in order to wear the Patch?